Table 4 Pathological features of patients with PD-L1+ and PD-L1− anaplastic large cell lymphoma

From: PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma

 

ALK+ ALCL (n = 45)

ALK− ALCL (n = 50)

PD-L1+a (n = 34)

PD-L1− (n = 11)a

P-valueb

PD-L1+a (n = 21)

PD-L1− (n = 29)

P-valuec

Morphologic type

      

  Common pattern

85% (29/34)

73% (8/11)

0.38

100% (21/21)

97% (28/29)

1

  Non-common pattern

14% (5/34)

27% (3/11)

 

0% (0/21)

3% (1/29)

 

Immunophenotype

      

  CD2+

38% (9/24)

71% (5/7)

0.2

50% (6/12)

83% (19/23)

0.059

  CD3+

23% (7/31)

45% (5/11)

0.24

38% (8/21)

63% (17/27)

0.14

  CD4+

68% (17/25)

33% (2/6)

0.17

89% (17/19)

81% (21/26)

0.68

  CD5+

42% (10/24)

43% (3/7)

1

40% (6/15)

58% (14/24)

0.33

  CD7+

23% (3/13)

33% (1/3)

1

27% (3/11)

37% (7/19)

0.7

  CD8+

5% (1/19)

17% (1/6)

0.43

0% (0/14)

13% (3/24)

0.28

  CD25+

100% (9/9)

67% (2/3)

0.25

100% (2/2)

60% (3/5)

1

  CD43+

65% (11/17)

100% (5/5)

0.27

70% (7/10)

100% (9/9)

0.21

  CD45+

68% (17/25)

75% (3/4)

1

73% (11/15)

92% (12/13)

0.33

  Granzyme B+

80% (8/10)

100% (4/4)

1

56% (5/9)

33% (2/6)

0.61

  EMA+

94% (16/17)

100% (5/5)

1

69% (9/13)

20% (3/15)

0.02

  1. ALCL anaplastic large cell lymphoma
  2. a≥5% of lymphoma cells were positive for PD-L1
  3. bALK+/PD-L1+  ALCL compared with ALK + /PD-L1− ALCL
  4. cALK−/PD-L1+  ALCL compared with ALK−/PD-L1− ALCL
Back to article page